DCMIC
ACET icon

Decheng Capital Management III (Cayman)’s Adicet Bio ACET Stock Holding History

Decheng Capital Management III (Cayman)’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$274K Sell
12,513
-19,091
-60% -$674K 0.09% 26
2023
Q2 		$1.23M Sell
31,604
-4,646
-13% -$410K 0.39% 22
2023
Q1 		$3.34M Hold
36,250
– – 1.35% 16
2022
Q4 		$5.19M Hold
36,250
– – 1.94% 15
2022
Q3 		$8.25M Hold
36,250
– – 2.99% 11
2022
Q2 		$8.47M Hold
36,250
– – 3.21% 9
2022
Q1 		$11.6M Buy
+36,250
New +$8.34M 3.55% 9

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Decheng Capital Management III (Cayman)'s ACET Position: Q3 2023 in Review

Decheng Capital Management III (Cayman) reduced its Adicet Bio (ACET) stake by 60% in Q3 2023, selling an estimated $674K and leaving 12,513 shares worth $274K. The position accounts for 0.09% of the portfolio, ranked #26.

Decheng Capital Management III (Cayman) first reported a position in ACET in Q1 2022 and has held it in 7 quarters since. The position peaked at $11.6M in Q1 2022. 83 funds tracked by Wall St. Rank hold ACET as of Q3 2023.

  • Decheng Capital Management III (Cayman) held 12,513 shares of Adicet Bio worth $274K as of Q3 2023.
  • Decheng Capital Management III (Cayman) sold 19,091 Adicet Bio shares in Q3 2023, an estimated $674K.
  • Adicet Bio made up 0.09% of Decheng Capital Management III (Cayman)'s portfolio in Q3 2023, its #26 holding.
  • Decheng Capital Management III (Cayman) first reported a position in Adicet Bio in Q1 2022 and has held it in 7 quarters since.
  • Decheng Capital Management III (Cayman)'s Adicet Bio position peaked at $11.6M in Q1 2022.
  • 83 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2023.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q3 2023, filed 13 Nov 2023.